Central venous access device infections in children with hemophilia: A comparison of prophylaxis and episodic therapy

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 7, 2007, Pages 458-464

  Hacker, Michele R ^a,b,c,f   Page, John H ^b   Shapiro, Amy D ^e   Rich Edwards, Janet W ^b,d   Manco Johnson, Marilyn J ^a  

^a Mountain States Regional Hemophilia and Thrombosis Center   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Central venous access device; CVAD; Hemophilia; Infection; Port

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 8;

ARTICLE; CENTRAL VEIN; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVICE INFECTION; DRUG DOSE REDUCTION; HEMOPHILIA A; HUMAN; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; VASCULAR ACCESS DEVICE;

CATHETERIZATION, CENTRAL VENOUS; CHILD, PRESCHOOL; EQUIPMENT CONTAMINATION; HEMOPHILIA A; HUMANS; INFANT; INFECTION; INFECTION CONTROL; MALE;

EID: 34347374513     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318068b1d6     Document Type: Article

References (33)

1. Khoriaty R, Taher A, Inati A, et al. A comparison between prophylaxis and on demand treatment for severe haemophilia. Clin Lab Haematol. 2005;27:320-323.
2. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol. 1996;92:973-978.
3. Lofqvist T, Nilsson IM, Berntorp E, et al. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med. 1997;241:395-400.
4. Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25-32.
5. Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr. 1996;129:424-431.
6. Aronstam A, McLellan DS, Turk P. Transfusion requirements of adolescents with severe haemophilia A. J Clin Pathol. 1979;32:927-930.
7. Aronstam A, Arblaster PG, Rainsford SG, et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol. 1976;33:81-90.
8. Miners AH, Sabin CA, Tolley KH, et al. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med. 1998;244:515-522.
9. Carlsson KS, Hojgard S, Lindgren A, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia. 2004;10:515-526.
10. Schramm W, Royal S, Kroner B, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia. 2002;8:33-43.
11. The National Hemophilia Foundation. Medical and Scientific Advisory Council Recommendations Concerning Prophylaxis. New York: The National Hemophilia Foundation; 1994.
12. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73:691-701.
13. Blanchette P, Rivard G, Israels S, et al. A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia. 2004;10:679-683.
14. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia. 2005;11:92-99.
15. Miners AH, Sabin CA, Tolley KH, et al. The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. Haemophilia. 1998;4:4-9.
16. Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood. 2004;104:3494-3500.
17. Van Den Berg HM, Fischer K, Roosendaal G, et al. The use of the Port-A-Cath in children with haemophilia - a review. Haemophilia. 1998;4:418-420.
18. Coyle VM, McMullan R, Morris TC, et al. Catheter-related bloodstream infection in adult haematology patients: catheter removal practice and outcome. J Hosp Infect. 2004;57:325-331.
19. Crary SE, Buchanan GR, Journeycake JM. Fatal central venous catheter-related infection in haemophilia. Haemophilia. 2006;12:183-186.
20. Manco-Johnson MJ, Nuss R, Geraghty S, et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol. 1994;47:113-117.
21. Li CH, Ou Y, Lee AC, et al. Septic arthritis in hemophilia with central venous catheter: a case report. Pediatr Hematol Oncol. 2000;17:187-189.
22. Hothi DK, Kelsall W, Baglin T, et al. Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters. Haemophilia. 2001;7:507-510.
23. Wiegand G, Rauch R, Effenberger W, et al. Cardiomyopathy following port-implantation for immune tolerance therapy. Haemophilia. 2002;8:490.
24. Valentino LA, Ewenstein B, Navickis RJ, et al. Central venous access devices in haemophilia. Haemophilia. 2004;10:134-146.
25. Blanchette VS, McCready M, Achonu C, et al. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia. 2003;9(suppl 1):19-26.
26. Ljung R, Van den BM, Petrini P, et al. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr. 1998;87:1051-1054.
27. Manco-Johnson MJ, Abshire TC, Brown D, et al. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood. 2005;106:6A-Abstract 3.
28. Manco-Johnson MJ, Blanchette VS. North American prophylaxis studies for persons with severe haemophilia: background, rationale and design. Haemophilia. 2003;9(suppl 1):44-48.
29. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1-29.
30. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373-379.
31. Lin DY, Wei LJ. The robust inference for the Cox Proportional Hazards Model. J Am Statist Assoc. 1989;84:1074-1078.
32. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Statist Assoc. 1989;84:1065-1073.
33. Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia. 2003;9(suppl 1):38-42.